We're delighted to add our latest Educational Series titled: Endometrial cancer treatment with lenvatinib (combined with pembrolizumab): early identification and management of adverse reactions.
This educational review discusses the treatment of endometrial cancer with lenvatinib in combination with pembrolizumab, with a focus on optimising patient outcomes and adherence through the early recognition and management of lenvatinib-associated adverse reactions.
It also includes guiding commentary from Adjunct Professor (Dr) Jeffrey Goh, an experienced Medical Oncologist consulting at ICON Cancer Centre Chermside, Wesley and Greenslopes Private Hospital. He is also part-time Senior Staff Specialist at Royal Brisbane & Women’s Hospital.
Please login below to download this issue (PDF)